Moore Capital Management LP Has $3.85 Million Position in Alumis Inc. $ALMS

Moore Capital Management LP grew its stake in Alumis Inc. (NASDAQ:ALMS) by 230.7% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 136,803 shares of the company’s stock after acquiring an additional 95,433 shares during the quarter. Moore Capital Management LP owned 0.11% of Alumis worth $3,850,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of ALMS. Russell Investments Group Ltd. increased its stake in Alumis by 320.9% in the third quarter. Russell Investments Group Ltd. now owns 6,419 shares of the company’s stock valued at $26,000 after purchasing an additional 4,894 shares in the last quarter. New York State Common Retirement Fund boosted its holdings in shares of Alumis by 173.7% in the second quarter. New York State Common Retirement Fund now owns 11,767 shares of the company’s stock valued at $35,000 after buying an additional 7,467 shares during the period. KBC Group NV bought a new stake in shares of Alumis during the first quarter worth $42,000. Strs Ohio raised its holdings in shares of Alumis by 300.0% during the first quarter. Strs Ohio now owns 2,000 shares of the company’s stock worth $44,000 after acquiring an additional 1,500 shares during the period. Finally, BNP Paribas Financial Markets lifted its position in Alumis by 104.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 11,770 shares of the company’s stock valued at $47,000 after acquiring an additional 6,027 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on ALMS shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Alumis in a research note on Tuesday, July 7th. Citigroup reissued a “neutral” rating on shares of Alumis in a research report on Monday, August 17th. Wall Street Zen upgraded Alumis from a “strong sell” rating to a “hold” rating in a research note on Sunday, August 23rd. Guggenheim upped their price target on Alumis from $32.00 to $34.00 and gave the stock a “buy” rating in a research report on Friday, May 15th. Finally, Wells Fargo & Company lifted their price objective on shares of Alumis from $49.00 to $51.00 and gave the company an “overweight” rating in a report on Friday, May 15th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Alumis currently has a consensus rating of “Moderate Buy” and an average price target of $40.30.

Alumis Stock Down 2.5%

NASDAQ:ALMS opened at $21.81 on Tuesday. Alumis Inc. has a 12-month low of $3.76 and a 12-month high of $31.35. The firm has a market capitalization of $2.82 billion, a price-to-earnings ratio of -5.65 and a beta of -0.69. The stock’s 50 day moving average price is $26.50 and its two-hundred day moving average price is $25.05.

Alumis (NASDAQ:ALMS) last posted its earnings results on Thursday, August 13th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.34). Alumis had a negative return on equity of 93.15% and a negative net margin of 5,933.46%.The company had revenue of $1.66 million for the quarter, compared to analyst estimates of $3.65 million. Equities research analysts expect that Alumis Inc. will post -2.95 EPS for the current year.

Insiders Place Their Bets

In related news, insider David M. Goldstein sold 2,596 shares of the stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $26.37, for a total value of $68,456.52. Following the completion of the sale, the insider directly owned 30,970 shares in the company, valued at $816,678.90. This represents a 7.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Roy C. Hardiman sold 2,692 shares of the firm’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $26.37, for a total value of $70,988.04. Following the transaction, the insider directly owned 207,746 shares of the company’s stock, valued at approximately $5,478,262.02. This represents a 1.28% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 19,953 shares of company stock worth $534,311 over the last quarter. 33.70% of the stock is currently owned by corporate insiders.

Alumis Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.